Omeros Co. (NASDAQ:OMER) – Stock analysts at Wedbush reduced their FY2020 EPS estimates for shares of Omeros in a research report issued on Thursday, Zacks Investment Research reports. Wedbush analyst L. Moussatos now expects that the biopharmaceutical company will post earnings of $1.47 per share for the year, down from their previous estimate of $1.81. Wedbush currently has a “Outperform” rating and a $47.00 price objective on the stock. Wedbush also issued estimates for Omeros’ FY2021 earnings at $2.39 EPS.
Omeros (NASDAQ:OMER) last released its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.18. The firm had revenue of $21.66 million for the quarter, compared to the consensus estimate of $17.82 million. The firm’s revenue for the quarter was up 91.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.34) earnings per share.
Other analysts also recently issued research reports about the stock. Maxim Group set a $24.00 price target on shares of Omeros and gave the company a “buy” rating in a report on Wednesday, January 3rd. HC Wainwright set a $30.00 price target on shares of Omeros and gave the company a “buy” rating in a report on Thursday, December 14th. Cowen downgraded shares of Omeros from an “outperform” rating to a “market perform” rating in a report on Thursday, November 2nd. Finally, Zacks Investment Research downgraded shares of Omeros from a “hold” rating to a “sell” rating in a report on Thursday, November 9th. Five research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Omeros has an average rating of “Buy” and a consensus target price of $34.14.
Omeros (NASDAQ:OMER) traded down $0.13 during trading hours on Monday, reaching $19.60. 259,900 shares of the company’s stock were exchanged, compared to its average volume of 754,411. The company has a market cap of $940.87, a price-to-earnings ratio of -15.19 and a beta of 3.56. The company has a debt-to-equity ratio of 8.99, a quick ratio of 4.74 and a current ratio of 4.77. Omeros has a 1-year low of $8.71 and a 1-year high of $27.09.
Several hedge funds and other institutional investors have recently made changes to their positions in OMER. Legal & General Group Plc boosted its holdings in shares of Omeros by 7.8% in the second quarter. Legal & General Group Plc now owns 10,359 shares of the biopharmaceutical company’s stock worth $208,000 after buying an additional 751 shares during the last quarter. Rhumbline Advisers boosted its holdings in shares of Omeros by 1.8% in the second quarter. Rhumbline Advisers now owns 46,632 shares of the biopharmaceutical company’s stock worth $928,000 after buying an additional 832 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in shares of Omeros by 1.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 197,665 shares of the biopharmaceutical company’s stock worth $3,935,000 after buying an additional 2,548 shares during the last quarter. Voya Investment Management LLC boosted its holdings in shares of Omeros by 20.7% in the second quarter. Voya Investment Management LLC now owns 19,300 shares of the biopharmaceutical company’s stock worth $384,000 after buying an additional 3,304 shares during the last quarter. Finally, Tocqueville Asset Management L.P. boosted its holdings in shares of Omeros by 0.7% in the third quarter. Tocqueville Asset Management L.P. now owns 480,896 shares of the biopharmaceutical company’s stock worth $10,397,000 after buying an additional 3,430 shares during the last quarter. 49.71% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: “FY2020 Earnings Forecast for Omeros Co. Issued By Wedbush (OMER)” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://ledgergazette.com/2018/01/15/wedbush-equities-analysts-reduce-earnings-estimates-for-omeros-co-omer.html.
Omeros Company Profile
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.